Bioceres Crop Solutions EPS Estimate Cut

Summary

Brookline Capital Management has revised downwards the FY2029 earnings per share (EPS) estimate for Bioceres Crop Solutions Corp. (NASDAQ: BIOX) from $0.97 to $0.82. The consensus estimate for the company’s full-year earnings is now ($0.05) per share. Other analysts have also adjusted their target prices: Oppenheimer from $8.00 to $7.00, and Canaccord Genuity from $7.00 to $6.50. Despite these changes, the stock maintains a ‘Buy’ consensus rating with a target price of $8.63.Market Beat

Impact Analysis

The event is classified at the company level as it specifically concerns Bioceres Crop Solutions. The downward revision in EPS estimates and target prices by Brookline Capital Management and other analysts reflects a negative sentiment following the company’s reported 28% revenue drop and a net loss of $1.6 million for Q3 FY2025.Reuters+ 2 This situation directly impacts investor expectations and could exert downward pressure on the stock price in the short term as market participants adjust their valuations based on the revised forecasts. The consensus ‘Buy’ rating and a target price of $8.63 suggest that some analysts still see potential upside, possibly due to underlying strengths or future strategic initiatives by the company. Investors should consider the risks associated with the company’s current financial performance and the broader market conditions that may affect the agricultural sector in which Bioceres operates.Market Beat+ 2